{
  "name": "Desvenlafaxine",
  "genericName": "desvenlafaxine",
  "brandNames": ["Pristiq", "Khedezla"],
  "tags": ["SNRI", "Antidepressant"],
  "dosing": {
    "adult_acute": "50 mg once daily",
    "adult_maintenance": "50 mg/day",
    "notes": "Active metabolite of venlafaxine; minimal benefit from doses >50 mg; take with or without food",
    "canadian_clinical": {
      "starting_dose": "50 mg once daily",
      "titration_schedule": "Can increase to 100 mg after 1 week if needed, but limited additional efficacy",
      "max_dose_evidence": "100 mg/day (no additional benefit shown above 50 mg)",
      "max_dose_practice": "50 mg/day (most patients); 100 mg occasionally used but not recommended",
      "inpatient_strategy": "Start 50 mg daily; minimal need for titration",
      "outpatient_strategy": "50 mg once daily; reassess at 4-6 weeks; limited evidence for dose increases"
    }
  },
  "warnings": [
    "Black box warning: Increased suicidal thinking in children/adolescents/young adults",
    "Discontinuation syndrome - taper slowly despite shorter half-life than venlafaxine",
    "Blood pressure increases (dose-dependent) - monitor BP",
    "Less drug interactions than venlafaxine (not metabolized by CYP2D6)",
    "Minimal evidence for superiority over venlafaxine; more expensive"
  ],
  "cautions": {
    "renal": "CrCl 30-50: Max 50 mg/day; CrCl <30: Max 50 mg every other day or 25 mg/day",
    "hepatic": "Max 100 mg/day (no dose adjustment for mild-moderate); use caution in severe",
    "pregnancy": "Pregnancy Category C; consider risks/benefits"
  },
  "citations": ["FDA Pristiq Label", "CANMAT Guidelines", "APA Guidelines"]
}
